Eye-Tracking Alcohol Warning
Public ClinicalTrials.gov record NCT07852013. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Eye-Tracking and Discrete Choice Experiments Testing Alcohol Cancer Risk Warning Labels: Implications for Policy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This pilot study will evaluate communication strategies that may improve public understanding of alcohol-related cancer risks and influence behavioral intentions. The study will compare graphic alcohol cancer warning labels with the current U.S. Surgeon General text-only warning label across two stages. The first stage is an in-person, lab-based eye-tracking experiment that will examine differences in visual attention, communication outcomes, harm perception, and behavioral intentions following exposure to graphic versus text-only warning labels. The second stage is a discrete choice experiment that will examine how warning label type, warning label size, and alcohol type (beer, wine, or liquor) influence participants' intentions to reduce or stop alcohol consumption and purchase alcohol. The study will recruit 50 adults aged 21 years or older who report regular alcohol consumption.
Study identification
- NCT ID
- NCT07852013
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 50 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 21 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2026 (Estimated)
- Primary completion
- Oct 1, 2027 (Estimated)
- Completion
- Oct 1, 2027 (Estimated)
- Last update posted
- Oct 1, 2026
2026 – 2027
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Miami - Rosenstiel Medical Science Building | Miami | Florida | 33136 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07852013, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 1, 2026 · Synced Oct 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07852013 live on ClinicalTrials.gov.